SOM3355: Pharmacological Profile for Movement and Neuropsychiatric Disorders

A 1.5 MB document authored by Emily S. Turilli-Ghisolfi, last updated on 2026-05-19. It describes the novel mechanism of action of the clinical drug candidate SOM3355, which combines VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism. The document details in vitro and in vivo studies supporting its potential for treating conditions like Huntington's disease, tardive dyskinesia, and Tourette Syndrome.

Use Cases

• Analyzing the pharmacological profile of a novel multi-target drug based on the described VMAT1, VMAT2, and β1-adrenergic activities.
• Studying potential therapeutic mechanisms for hyperkinetic movement disorders based on the described monoamine neurotransmitter modulation.
• Comparing the interaction mode of SOM3355 with existing VMAT2 inhibitors like tetrabenazine based on the described binding affinity differences.
• Investigating the rationale for combined motor and neuropsychiatric symptom treatment in complex disorders based on the described clinical effects.

Strengths

• Document is 1.5 MB in size, providing a detailed pharmacological profile.
• The description includes specific comparisons to established drugs like tetrabenazine.
• The license is CC-BY-4.0, permitting open sharing and adaptation.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The data is contained in a DOCX file, which may require specific tools for structured analysis.

Provenance

Source

figshare

Collection Method

Likely contains research findings and data from in vitro and in vivo studies.

Freshness

Last updated 2026-05-19 05:28:36; freshness should be verified.